Medicus Pharma Ltd. has made significant strides in its third-quarter performance, announcing a strategic partnership with Pfizer and a proposed business combination involving its subsidiary SkinJect. This update is crucial for the company as it positions itself for growth in the competitive pharmaceutical landscape.
Founded as a precision-guided biotech company, Medicus Pharma Ltd. focuses on advancing clinical development programs for novel therapeutic assets. It operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on Nasdaq under the tickers MDCX and MDCXW.
In its recent SEC filing dated November 6, 2026, Medicus reported its financial results for the third quarter of 2026. The company highlighted a co-development and license agreement with Pfizer for its clinical-stage antibody-drug conjugate, CD228V, which targets melanotransferrin. Medicus has designated CD228V as its principal development priority, aiming to establish clinical proof-of-concept in melanoma.
During the quarter, Medicus achieved several milestones, including an exclusive development focus for SkinJect in treating Gorlin syndrome and the submission of a registrational protocol for Teverelix to the FDA for advanced prostate cancer. The company also announced a non-binding letter of intent for a proposed business combination between SkinJect and an undisclosed special purpose acquisition company (SPAC).
Dr. Raza Bokhari, Medicus's Executive Chairman and CEO, stated, "The third quarter saw the transformation of Medicus into a precision oncology-led biotech company with CD228V as our principal development priority. With capital-efficient allocation of resources, we remain focused on disciplined execution, regulatory excellence, and strategic growth as we seek to build long-term shareholder value and advance therapies with the potential to improve patient outcomes."
Financially, Medicus reported cash and cash equivalents of $5.0 million, a decrease from $8.7 million as of December 31, 2025. The total operating expenses for the quarter were $14.5 million, compared to $15.4 million in the same quarter of the previous year. The net loss for Q3 2026 was $15.2 million, down from $16.0 million in Q3 2025.
Looking ahead, Medicus plans to concentrate its resources on the development of CD228V while pursuing the proposed business combination for SkinJect and seeking strategic partnerships for Teverelix. The company aims to maintain its focus on capital efficiency and disciplined execution in the coming quarters.
Details regarding the proposed business combination and future developments are expected in subsequent filings with the SEC. The company remains committed to advancing its therapeutic assets and enhancing shareholder value.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










